Host: Jennifer Caudle, DO

Guest: James McCloskey II, MD

Capillary leak syndrome (CLS) is a condition of vascular permeability that’s associated with tagraxofusp (TAG), a CD123-directed therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).1 Early recognition of signs and symptoms of CLS is critical to reduce patients’ risk of severe sequelae, which can include multi-organ failure and death.2-4 Joining Dr. Jennifer Caudle to discuss strategies for early identification and intervention of CLS in BPDCN patients treated with TAG is Dr. James McCloskey. Dr. James McCloskey is the Chief of the Division of Leukemia at Hackensack Meridian John Theurer Cancer Center, part of Hackensack University Medical Center.

Dr. McCloskey has received compensation from Stemline to present the following information on behalf of Stemline.

References:

1. Tagraxofusp-erzs [package insert], New York, NY; Stemline Therapeutics, Inc.
2. Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92(1):37–46. doi:10.1016/j.kint.2016.11.029
3. Clinicaltrials.gov. CTCAE. Accessed May 21, 2025. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_ quick_reference_8.5x11.pdf
4. Pemmaraju N, Madanat YF, Rizzieri D, et al. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma. 2024;65(5):548–559. doi:10.1080/10428194.2024.2305288